Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Stefan K. Barta"'
Autor:
James N. Gerson, Stefan K. Barta, Kyle W. Robinson, Sunita D. Nasta, Jakub Svoboda, Daniel J. Landsburg, Stephen J. Schuster, Elise A. Chong, Mitchell E. Hughes
Publikováno v:
Leukemia & Lymphoma. 63:243-246
Polatuzumab vedotin (PV), an anti-CD79b antibody drug conjugate, was approved by the United States (US) Food and Drug Administration in June 2019 for relapsed/refractory diffuse large B cell lympho...
Publikováno v:
Cancer Biology & Therapy. 19:101-104
A 67-year-old male presented with anasarca and persistent non-pruritic rash of lower extremities. Physical examination was positive for subcutaneous edema with a non-blanching rash of abdomen and lower extremities. Labs showed leukocytosis, lymphocyt
Autor:
Stefan K. Barta, Joseph A. Sparano, Michelle A. Rudek, Carlyn Rose C. Tan, Ariela Noy, Jeannette Y. Lee
Publikováno v:
Leukemia & Lymphoma. 59:1851-1860
Drug-drug interactions between cART and chemotherapy may impact HIV and lymphoma control or lead to increased toxicities. No prospective comparative data informs potential harms and benefits. In AMC034 HIV-associated high-grade B-cell NHL patients re
Autor:
Tushar D. Bhagat, Yiyu Zou, Amit Verma, Ulrich Steidl, Niraj Shenoy, Stefan K. Barta, John Schindler
Publikováno v:
Leukemia & Lymphoma. 53:1999-2003
The outcome for patients with refractory or relapsed acute lymphoblastic leukemia (ALL) treated with conventional therapy is poor. Immunoconjugates present a novel approach and have recently been shown to have efficacy in this setting. Combotox is a